|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BCL10 |
Gene summary for BCL10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BCL10 | Gene ID | 8915 |
| Gene name | BCL10 immune signaling adaptor | |
| Gene Alias | CARMEN | |
| Cytomap | 1p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | A2TDT2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8915 | BCL10 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.13e-04 | 4.54e-01 | -0.1808 |
| 8915 | BCL10 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.28e-12 | 4.65e-01 | -0.1954 |
| 8915 | BCL10 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.75e-03 | 9.47e-01 | -0.2602 |
| 8915 | BCL10 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.11e-09 | 3.74e-01 | 0.294 |
| 8915 | BCL10 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.59e-03 | 2.38e-01 | 0.3859 |
| 8915 | BCL10 | LZE4T | Human | Esophagus | ESCC | 5.96e-05 | 6.61e-01 | 0.0811 |
| 8915 | BCL10 | LZE8T | Human | Esophagus | ESCC | 1.52e-03 | 3.07e-01 | 0.067 |
| 8915 | BCL10 | LZE22D1 | Human | Esophagus | HGIN | 4.08e-03 | -1.31e-01 | 0.0595 |
| 8915 | BCL10 | LZE22T | Human | Esophagus | ESCC | 8.11e-05 | 4.14e-01 | 0.068 |
| 8915 | BCL10 | LZE24T | Human | Esophagus | ESCC | 6.42e-04 | 4.01e-01 | 0.0596 |
| 8915 | BCL10 | P1T-E | Human | Esophagus | ESCC | 3.22e-06 | 7.42e-01 | 0.0875 |
| 8915 | BCL10 | P2T-E | Human | Esophagus | ESCC | 5.95e-18 | 3.46e-01 | 0.1177 |
| 8915 | BCL10 | P4T-E | Human | Esophagus | ESCC | 1.41e-10 | 6.00e-01 | 0.1323 |
| 8915 | BCL10 | P5T-E | Human | Esophagus | ESCC | 6.15e-28 | 7.99e-01 | 0.1327 |
| 8915 | BCL10 | P8T-E | Human | Esophagus | ESCC | 1.66e-09 | 1.91e-01 | 0.0889 |
| 8915 | BCL10 | P9T-E | Human | Esophagus | ESCC | 2.09e-03 | 5.62e-02 | 0.1131 |
| 8915 | BCL10 | P10T-E | Human | Esophagus | ESCC | 6.35e-13 | 1.24e-01 | 0.116 |
| 8915 | BCL10 | P11T-E | Human | Esophagus | ESCC | 7.49e-08 | 7.39e-01 | 0.1426 |
| 8915 | BCL10 | P12T-E | Human | Esophagus | ESCC | 1.91e-46 | 1.47e+00 | 0.1122 |
| 8915 | BCL10 | P15T-E | Human | Esophagus | ESCC | 1.34e-11 | 3.56e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:200105624 | Skin | cSCC | positive regulation of cysteine-type endopeptidase activity | 55/4864 | 148/18723 | 1.73e-03 | 1.06e-02 | 55 |
| GO:003367425 | Skin | cSCC | positive regulation of kinase activity | 148/4864 | 467/18723 | 3.00e-03 | 1.66e-02 | 148 |
| GO:003514822 | Skin | cSCC | tube formation | 54/4864 | 148/18723 | 3.00e-03 | 1.66e-02 | 54 |
| GO:007217521 | Skin | cSCC | epithelial tube formation | 49/4864 | 132/18723 | 3.06e-03 | 1.68e-02 | 49 |
| GO:004578529 | Skin | cSCC | positive regulation of cell adhesion | 139/4864 | 437/18723 | 3.39e-03 | 1.84e-02 | 139 |
| GO:005109214 | Skin | cSCC | positive regulation of NF-kappaB transcription factor activity | 55/4864 | 152/18723 | 3.40e-03 | 1.84e-02 | 55 |
| GO:000961224 | Skin | cSCC | response to mechanical stimulus | 73/4864 | 216/18723 | 6.22e-03 | 3.04e-02 | 73 |
| GO:005085221 | Skin | cSCC | T cell receptor signaling pathway | 44/4864 | 123/18723 | 1.02e-02 | 4.47e-02 | 44 |
| GO:1903320113 | Thyroid | PTC | regulation of protein modification by small protein conjugation or removal | 148/5968 | 242/18723 | 4.49e-21 | 8.10e-19 | 148 |
| GO:2001233113 | Thyroid | PTC | regulation of apoptotic signaling pathway | 197/5968 | 356/18723 | 2.58e-20 | 3.69e-18 | 197 |
| GO:0031396113 | Thyroid | PTC | regulation of protein ubiquitination | 128/5968 | 210/18723 | 3.06e-18 | 3.27e-16 | 128 |
| GO:0045862113 | Thyroid | PTC | positive regulation of proteolysis | 198/5968 | 372/18723 | 6.68e-18 | 6.91e-16 | 198 |
| GO:0097191113 | Thyroid | PTC | extrinsic apoptotic signaling pathway | 117/5968 | 219/18723 | 2.73e-11 | 1.03e-09 | 117 |
| GO:0071496113 | Thyroid | PTC | cellular response to external stimulus | 158/5968 | 320/18723 | 4.12e-11 | 1.47e-09 | 158 |
| GO:0071214111 | Thyroid | PTC | cellular response to abiotic stimulus | 158/5968 | 331/18723 | 9.90e-10 | 2.89e-08 | 158 |
| GO:0104004111 | Thyroid | PTC | cellular response to environmental stimulus | 158/5968 | 331/18723 | 9.90e-10 | 2.89e-08 | 158 |
| GO:2001236113 | Thyroid | PTC | regulation of extrinsic apoptotic signaling pathway | 82/5968 | 151/18723 | 9.01e-09 | 2.18e-07 | 82 |
| GO:2001235112 | Thyroid | PTC | positive regulation of apoptotic signaling pathway | 69/5968 | 126/18723 | 8.51e-08 | 1.73e-06 | 69 |
| GO:000184118 | Thyroid | PTC | neural tube formation | 58/5968 | 102/18723 | 1.59e-07 | 3.03e-06 | 58 |
| GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
| hsa051312 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| hsa051313 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
| hsa051314 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
| hsa051315 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
| hsa0513139 | Esophagus | HGIN | Shigellosis | 71/1383 | 247/8465 | 4.89e-07 | 7.98e-06 | 6.34e-06 | 71 |
| hsa05131114 | Esophagus | HGIN | Shigellosis | 71/1383 | 247/8465 | 4.89e-07 | 7.98e-06 | 6.34e-06 | 71 |
| hsa05131211 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa046259 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
| hsa051527 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
| hsa040645 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
| hsa046607 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
| hsa05131310 | Esophagus | ESCC | Shigellosis | 176/4205 | 247/8465 | 2.27e-12 | 4.01e-11 | 2.05e-11 | 176 |
| hsa0462513 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
| hsa0515212 | Esophagus | ESCC | Tuberculosis | 111/4205 | 180/8465 | 7.14e-04 | 2.32e-03 | 1.19e-03 | 111 |
| hsa0406412 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
| hsa0466013 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
| hsa0513142 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
| hsa0513152 | Liver | HCC | Shigellosis | 150/4020 | 247/8465 | 1.53e-05 | 1.04e-04 | 5.81e-05 | 150 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BCL10 | SNV | Missense_Mutation | novel | c.276G>T | p.Gln92His | p.Q92H | O95999 | protein_coding | deleterious(0.02) | probably_damaging(0.969) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BCL10 | SNV | Missense_Mutation | c.262C>G | p.Arg88Gly | p.R88G | O95999 | protein_coding | deleterious(0.01) | probably_damaging(0.945) | TCGA-C8-A1HK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| BCL10 | SNV | Missense_Mutation | c.682N>T | p.Arg228Cys | p.R228C | O95999 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| BCL10 | SNV | Missense_Mutation | novel | c.256N>C | p.Ile86Leu | p.I86L | O95999 | protein_coding | deleterious(0.04) | possibly_damaging(0.56) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| BCL10 | insertion | Frame_Shift_Ins | rs387906351 | c.136_137insA | p.Ile46AsnfsTer4 | p.I46Nfs*4 | O95999 | protein_coding | TCGA-D8-A140-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin+cyclophosphamid | SD | ||
| BCL10 | SNV | Missense_Mutation | c.682N>T | p.Arg228Cys | p.R228C | O95999 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-VS-A957-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| BCL10 | SNV | Missense_Mutation | novel | c.415N>A | p.Asp139Asn | p.D139N | O95999 | protein_coding | tolerated(0.46) | benign(0) | TCGA-XS-A8TJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| BCL10 | SNV | Missense_Mutation | c.322A>C | p.Asn108His | p.N108H | O95999 | protein_coding | tolerated(0.06) | possibly_damaging(0.707) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| BCL10 | SNV | Missense_Mutation | novel | c.200N>C | p.Lys67Thr | p.K67T | O95999 | protein_coding | tolerated(0.17) | probably_damaging(0.951) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BCL10 | SNV | Missense_Mutation | c.235N>A | p.Leu79Met | p.L79M | O95999 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |